Eli Lilly said on Wednesday the U.S. health regulator has approved its drug to treat adults with moderate-to-severe Crohn's ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...

Companies from Johnson & Johnson to Eli Lilly, Amazon and Nvidia are announcing health-related deals at the JPMorgan Health ...

Eli Lilly forecast sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...

Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...